FDA Approves Hemangeol For Treating Infantile Hemangioma

Pierre Fabre Dermatologie March 17 announced that the Food and Drug Administration has approved the pediatric drug Hemangeol (propranolol hydrochloride), the first and only approved treatment for proliferating infantile hemangioma requiring systemic therapy.

Infantile hemangiomas, sometimes referred to as “strawberry” marks, are collections of blood vessels that have increased cell division and growth.

Hemangeol is an oral solution specially developed for safe and effective use in children, the France-based company said. Hemangeol will be available June.

The new drug application for Hemangeol was submitted to the FDA in May 2013.

Serious Side Effects.

Hemangeol can cause serious side effects including ...